LY 2510924

Drug Profile

LY 2510924

Alternative Names: Anti-CXCR4 peptide - Eli Lilly; T-134

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer AstraZeneca; Eli Lilly; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Peptides; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Renal cell carcinoma; Small cell lung cancer
  • Phase I Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 01 Sep 2016 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (SC) (NCT02737072)
  • 01 May 2016 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (SC) (NCT02652871)
  • 08 Apr 2016 Eli Lilly and AstraZeneca plan a phase Ia/Ib trial for Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (SC) (NCT02737072)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top